An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function-Reference-Cited by-同舟云学术

An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

Published:2014-07-03 Issue:12 Volume:54 Page:1407-1420
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Moore Kenneth T.¹,Vaidyanathan Seema¹,Natarajan Jaya²,Ariyawansa Jay²,Haskell Lloyd²,Turner Kenneth C.¹

Affiliation:

1. Janssen Research and DevelopmentLLCTitusvilleNJUSA

2. Janssen Research and DevelopmentLLCRaritanNJUSA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.352

Reference24 articles.

1. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

2. Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2013. Available at:http://www.xarelto.com/en/information‐on‐xarelto/summary‐of‐product‐characteristics/Accessed May 1 2014.

3. Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery;Bauer KA;Blood (ASH Annual Meeting Abstracts),2008

4. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

5. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory Considerations in Metabolism‐ and Transport‐Based Drug Interactions;Oral Bioavailability and Drug Delivery;2023-10-10

2. Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach;Cardiovascular Drugs and Therapy;2023-03-04

3. Negative effects of rivaroxaban observed in a patient with multiple common risks triggered by a bicycle accident;Clinical Case Reports;2023-01

4. Oral drugs against COVID-19;Deutsches Ärzteblatt international;2022-04-15

5. Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction;Expert Opinion on Drug Metabolism & Toxicology;2022-03-04